News | May 18, 2021
Sputnik V launch to lift near-term outlook for Dr. Reddy's Labs: HDFC Securities
Dr. Reddy's has the rights to distribute 250mn doses in India
Dr. Reddy's has the rights to distribute 250mn doses in India
India sales grew 23.5% YoY with consolidation of Wockhardt products
Financial support is being provided as a grant from the Government of India
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The company is working closely with its six manufacturing partners in India
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Subscribe To Our Newsletter & Stay Updated
